Adagene (ADAG) investor relations material

Executive summary

• Muzastotug demonstrated a 29% confirmed overall response rate in 20 mg/kg cohorts for MSS CRC and a median overall survival of 19.4 months in 10 mg/kg cohorts, with favorable safety and tolerability across all dose levels.

• Enrollment in the randomized Phase 2 trial is ahead of plan, with results expected in 1H 2027 and a registration trial to begin after optimal dosing is established.

• Cash and cash equivalents stood at $74.5 million at year-end 2025, with additional proceeds from an ATM offering in 2026, providing a cash runway into early 2028.

Financial highlights

• Net revenue reached $7.7 million for 2025, up from $0.1 million in 2024, driven by collaboration and licensing agreements.

• R&D expenses decreased 23% year-over-year to $22.0 million, reflecting clinical prioritization.

• Administrative expenses were $7.1 million, down slightly from $7.3 million in 2024 due to cost controls.

• Net loss attributable to shareholders was $17.6 million, a significant improvement from $33.4 million in 2024.

• Non-GAAP net loss was $13.9 million, compared to $28.5 million in 2024.

Outlook and guidance

• Cash runway is expected to extend into early 2028, supported by year-end cash and recent ATM proceeds.

• Key 2026 objectives include completing Phase 2 enrollment, providing preliminary and initial clinical data from ongoing studies, and establishing new collaborations.